1,3-Dimethoxybenzene

1,3-Dimethoxybenzene

SCHEMBL2348353

COc1cccc(OC)c1.OBO

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.58
ALDH1A1 P00352 2/20 0.56
CYP3A4 P08684 2/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
CES2 O00748 1/20 0.56
CES1 P23141 1/20 0.56
ENPP2 Q13822 1/20 0.56
LMNA P02545 1/20 0.53
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
PARP1 P09874 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
PRSS1 P07477 1/20 0.52
PRSS2 P07478 1/20 0.52
PRSS3 P35030 1/20 0.52
CYP1A1 P04798 1/20 0.50
CYP1A2 P05177 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
1,3-Dimethoxybenzene SCHEMBL27700724 0.89 ACHE (0.64) ACHEALDH1A1CYP3A4CA1CA2
1,3-Dimethoxybenzene SCHEMBL9350 0.89 ACHE (0.70) ACHEALDH1A1CYP3A4CA1CA2
1,3-Dimethoxybenzene SCHEMBL901285 0.89 ACHE (0.70) ACHEALDH1A1CYP3A4CA1CA2
1-Hydroxy-3-Methoxybenzene SCHEMBL2432507 0.86 ESR1 (0.59) ACHEALDH1A1CYP3A4CA1CA2
SCHEMBL2604701 0.86 ACHE (0.50) ACHEALDH1A1CYP3A4CA1CA2
SCHEMBL3217844 0.86 ACHE (0.83) ACHEALDH1A1CYP3A4CA1CA2
1,3-Dimethoxybenzene SCHEMBL28343465 0.86 ACHE (0.67) ACHEALDH1A1CYP3A4CA1CA2
1,3-Dimethoxybenzene SCHEMBL7860661 0.86 ACHE (0.67) ACHEALDH1A1CYP3A4CA1CA2
1,3-Dimethoxybenzene SCHEMBL28542304 0.86 ACHE (0.67) ACHEALDH1A1CYP3A4CA1CA2
1,3-Dimethoxybenzene SCHEMBL15870025 0.86 ACHE (0.67) ACHEALDH1A1CYP3A4CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709724-A1 ANTICONVULSIVE COMPOUNDS AND USES THEREOF Jazz Pharmaceuticals Research UK Limited (GB) 2026-03-18 EP disclosed
WO-2024236275-A1 ANTICONVULSIVE COMPOUNDS AND USES THEREOF JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) 2024-11-21 WO disclosed
US-20220389008-A1 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 US disclosed
EP-4038067-A1 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2022-08-10 EP disclosed
WO-2021063914-A1 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2021-04-08 WO disclosed
WO-2019233438-A1 KINASE SELECTIVE INHIBITOR 北京大学深圳研究生院 (CN) 2019-12-12 WO disclosed
US-8008301-B2 (2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4'-trifluoromethyl-biphenyl-4-yl)-methanone; treatment of nervous system disorder, obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases ELI LILLY AND COMPANY (US) 2011-08-30 US disclosed
US-20100048580-A1 HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES BEAVERS LISA SELSAM 2010-02-25 US disclosed
US-7666871-B2 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy ELI LILLY AND COMPANY (US) 2010-02-23 US disclosed
EP-1735278-B1 HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES LILLY CO ELI (US) 2010-01-06 EP disclosed
EP-1332132-A2 ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES Celltech R&D Limited (GB) 2003-08-06 EP disclosed
EP-1244611-A1 SQUARIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS Celltech R&D Limited (GB) 2002-10-02 EP disclosed
US-6455539-B2 AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIPROLIFERATORY AGENTS CELLTECH R&D LIMITED (GB) 2002-09-24 US disclosed
WO-2002070493-A1 BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY PHARMACOPEIA, INC. (US) 2002-09-12 WO disclosed
US-6403584-B1 CONJUNCTIVITIS, ALLERGIC RHINITIS, ALZHEIMER'S DISEASE, ASTHMA, ATHEROSCLEROSIS, AUTOLOGOUS BONE MARROW TRANSPLANTATION, ANTIINFLAMMATORY, ETC MERCK & CO., INC. 2002-06-11 US disclosed
US-20020037909-A1 Enamine derivatives UCB PHARMA S.A. (BE) 2002-03-28 US disclosed
WO-2001079173-A2 ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES CELLTECH R & D LIMITED (GB) 2001-10-25 WO disclosed
US-20010020017-A1 Squaric acid derivatives CELLTECH R&D LIMITED (GB) 2001-09-06 US disclosed
WO-2001047867-A1 SQUARIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS CELLTECH R & D LIMITED (GB) 2001-07-05 WO disclosed
WO-2000071572-A1 SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS MERCK & CO., INC. (US) 2000-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037909-A1 Enamine derivatives CCR1, ITGB2, CCR10 ACHE 3793/4885ALDH1A1 1142/4885CYP3A4 1265/4885
US-20100048580-A1 HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES HRH3, HRH4, HCRTR1 ACHE 334/4885ALDH1A1 2304/4885CYP3A4 2149/4885
US-20010020017-A1 Squaric acid derivatives SUCNR1, HCAR1, CCR1 ACHE 4486/4885ALDH1A1 282/4885CYP3A4 3941/4885
US-20220389008-A1 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS NQO2, NDUFS3, QARS1 ACHE 731/4885ALDH1A1 1097/4885CYP3A4 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.